vealed elevated protein level of 72 mg/dl and 3 white blood cells with no neoplastic cells, therefore providing no evidence of malignancy or CNS infection. Antiepileptic medications were started, and the patient underwent a right temporal brain and leptomeningeal biopsy. Pathology revealed idiopathic leptomeningeal inflammation and fibrosis without brain involvement. The patient improved clinic...

Breast cancer metastatic to the brain and/or leptomeningeal spread of disease is a frequently encountered clinical situation, especially given the extended course of disease in these patients. Systemic therapies can often effectively prolong extracranial disease control, making effective strategies to control central nervous system-based disease even more critical. We present a case of bulky le...

Abstract Leptomeningeal disease (LMD) in breast cancer carries a poor prognosis with median overall survival (OS) of 3-4 months. Recent series have indicated prolongation OS up to 10-13 months HER2-positive LMD treated intrathecal (IT) trastuzumab. Here we present an unprecedented long-term clinical, radiographic, and molecular response for more than 10 years on IT A 52-year-old woman presented...

Background Leptomeningeal metastasis (LM) from solid tumors may be diagnosed in approximately 10% of patients with metastatic cancer and can occur virtually all malignant tumors. Median overall survival (OS) is poor limited to a few months LM-directed treatment, including available targeted therapy, immunotherapy radiation therapy. Omburtamab specifically binds B7-H3 (CD276), transmembrane glyc...